CALL TO ACTION TO IMPROVE DETECTION AND MANAGEMENT OF HEPATIC ENCEPHALOPATHY IN EUROPE

LONDON, UK, Monday 28 September 2015, 07:00 GMT+1 – Norgine B.V. today announced that it has sponsored a new campaign led by the European Liver Patients Association (ELPA). Time to DeLiver: Optimising Patient Outcomes in Hepatic Encephalopathy, Abstract P38 was presented at the weekend at the EASL Special Conference, 25-27 September, Glasgow.1
The campaign 'Time to DeLiver' aims to drive greater awareness of hepatic encephalopathy and its impact on patients and their families, health systems and policy makers, and to improve identification and management of this debilitating condition.[i] The full campaign report 'Time To DeLiver: Getting a Grip on Hepatic Encephalopathy' will be launched on Monday 12 October at 18:30 at the European Parliament, Brussels.
Hepatic encephalopathy is a potentially life-threatening neuropsychiatric condition associated with liver disease. Hepatic encephalopathy affects approximately 200,000 people in Europe who suffer from advanced chronic liver disease.[ii],[iii] Hepatic encephalopathy remains underdiagnosed and under-treated, resulting in poor quality of life for patients and high burden on their carers, families and society.
To register to attend the launch of the report on Monday 12 October 2015 please contact: [email protected]

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.